Spots Global Cancer Trial Database for Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Official Title: A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Study ID: NCT04699188
Study Description
Brief Summary: This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Emory University School of Medicine/Winship Cancer Institute Winship Cancer Center, Atlanta, Georgia, United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
WA Uni School Of Med ., Saint Louis, Missouri, United States
Providence Cancer Center, Portland, Oregon, United States
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Uni of TX MD Anderson Cancer Cntr Dept of MD Anderson CancerCent, Houston, Texas, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Fuzhou, Fujian, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Nanchang, Jiangxi, China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Copenhagen, , Denmark
Novartis Investigative Site, Lyon, , France
Novartis Investigative Site, Marseille, , France
Novartis Investigative Site, Villejuif, , France
Novartis Investigative Site, Dresden, , Germany
Novartis Investigative Site, Essen, , Germany
Novartis Investigative Site, Freiburg, , Germany
Novartis Investigative Site, Koeln, , Germany
Novartis Investigative Site, Hong Kong, , Hong Kong
Novartis Investigative Site, Brescia, BS, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Nagoya, Aichi, Japan
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Yokohama-city, Kanagawa, Japan
Novartis Investigative Site, Osaka-city, Osaka, Japan
Novartis Investigative Site, Chuo ku, Tokyo, Japan
Novartis Investigative Site, Koto ku, Tokyo, Japan
Novartis Investigative Site, Osaka, , Japan
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Amsterdam, , Netherlands
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Malaga, Andalucia, Spain
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site, Santiago De Compostela, Galicia, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Tainan, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
